Amylin Obesity Trial Stopped Due to Safety Questions
By Catherine Shaffer
Thursday, March 17, 2011
Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. have become the latest drugmakers to be stymied by safety signals in clinical trials of an obesity candidate. The companies have suspended an ongoing study of pramlintide/metreleptin for obesity.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.